Relationship between atorvastatin dose and the harm caused by torcetrapib

Relationship between atorvastatin dose and the harm caused by torcetrapib

Development of the cholesteryl ester transfer protein (CETP) inhibitor, torcetrapib, was halted after the ILLUMINATE trial revealed an increase in both all-cause mortality (ACM) and major cardiovascular events (MCVEs) associated with its use. We now report that the harm caused by torcetrapib was con...

Full description

Bibliographic Details
Main Authors: Philip J. Barter, Kerry-Anne Rye, Mohan S. Beltangady, William C. Ports, William T. Duggan, S. Matthijs Boekholdt, David A. DeMicco, John J.P. Kastelein, Charles L. Shear
Format: Article
Language:English
Published: Elsevier 2012-11-01
Series:Journal of Lipid Research
Subjects:
atherosclerosis
cardiovascular diseases
cholesteryl ester transfer protein
cholesterol
drugs
lipoproteins
Online Access:http://www.sciencedirect.com/science/article/pii/S002222752041260X

Internet

http://www.sciencedirect.com/science/article/pii/S002222752041260X

Similar Items